HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gestin, J. F. Articles by Faivre-Chauvet, A. Search for Related Content PubMed PubMed Citation Articles by Gestin, J. F. Articles by Faivre-Chauvet, A.

Two-Step Targeting of Xenografted Colon Carcinoma Using a Bispecific Antibody and ¹⁸⁸Re-Labeled Bivalent Hapten: Biodistribution and Dosimetry Studies

Institut de Biologie, Institut National de la Santé et de la Recherche Médicale, Nantes; Hopital St. Antoine, Institut National de la Santé et de la Recherche Médicale, Paris; and Immunotech, Marseille, France

Radioimmunotherapy (RIT) is currently being considered for the treatment of solid tumors. Although results have been encouraging for pretargeted ¹³¹I RIT with the affinity enhancement system (AES), the radionuclide used is not optimal because of its long half-life, strong emission, poor specific activity, and low ß particle energy. ¹⁸⁸Re, though unsuitable for direct antibody labeling, could be used with the AES two-step targeting technique. The purpose of this study was to compare the distribution and dosimetry of a bivalent hapten labeled with ¹⁸⁸Re or ¹²⁵I. For dosimetry calculations and biodistribution data, ¹²⁵I was substituted for ¹³¹I. Methods: After preliminary injection of a bispecific anticarcinoembryonic antigen (CEA) or antihapten antibody (Bs-mAb F6-679), AG 8.1 or AG 8.0 hapten radiolabeled with ¹⁸⁸Re or ¹²⁵I was injected into a nude mouse model grafted subcutaneously with a human colon carcinoma cell line (LS-174-T) expressing CEA. A dosimetry study was performed for each animal from the concentration of radioactivity in tumor and different tissues. Results: Radiolabeling of AG 8.1 with ¹²⁵I afforded a 40% yield with a specific activity of 11.1 MBq/nmol after purification. Radiolabeling of AG 8.0 with ¹⁸⁸Re afforded a 72% yield with a specific activity of 31.82 MBq/nmol. In all experiments, the percentage of tumor uptake of ¹²⁵I-AG 8.1 was always significantly greater than that of ¹⁸⁸Re-AG 8.0. The corresponding tumor-to-tissue ratios reflected uptake values. The least favorable tumor-to-normal tissue ratios in the dosimetry study were 8.1 and 8.5 for ¹³¹I (tumor-to-blood ratio and tumor-to-kidney ratio, respectively) and 2.3 for ¹⁸⁸Re (tumor-to-intestine ratio). Conclusion: This study indicates that ¹⁸⁸Re can be used for radiolabeling of hapten in two-step radioimmunotherapy protocols with the AES technique. ¹⁸⁸Re has a greater range than ¹³¹I, which should allow the treatment of solid tumors around 1 cm in diameter. Although the method used for hapten radiolabeling did not provide optimal tumor uptake, the use of a bifunctional chelating agent associated with AG 8.1 should solve this problem.

Key Words: ¹⁸⁸Re • radioimmunotherapy • bispecific antibody • pretargeting

This article has been cited by other articles:

				W. J. McBride, P. Zanzonico, R. M. Sharkey, C. Noren, H. Karacay, E. A. Rossi, M. J. Losman, P.-Y. Brard, C.-H. Chang, S. M. Larson, et al. Bispecific Antibody Pretargeting PET (ImmunoPET) with an 124I-Labeled Hapten-Peptide J. Nucl. Med., October 1, 2006; 47(10): 1678 - 1688. [Abstract] [Full Text] [PDF]

				G. Liu, S. Dou, G. Mardirossian, J. He, S. Zhang, X. Liu, M. Rusckowski, and D. J. Hnatowich Successful Radiotherapy of Tumor in Pretargeted Mice by 188Re-Radiolabeled Phosphorodiamidate Morpholino Oligomer, a Synthetic DNA Analogue. Clin. Cancer Res., August 15, 2006; 12(16): 4958 - 4964. [Abstract] [Full Text] [PDF]

				F. G. van Schaijk, E. Oosterwijk, A. C. Soede, M. Broekema, C. Frielink, W. J. McBride, D. M. Goldenberg, F. H.M. Corstens, and O. C. Boerman Pretargeting of Carcinoembryonic Antigen-Expressing Tumors with a Biologically Produced Bispecific Anticarcinoembryonic Antigen x Anti-Indium-Labeled Diethylenetriaminepentaacetic Acid Antibody Clin. Cancer Res., October 1, 2005; 11(19): 7130s - 7136s. [Abstract] [Full Text] [PDF]

				F. G. van Schaijk, E. Oosterwijk, J. D. Molkenboer-Kuenen, A. C. Soede, B. J. McBride, D. M. Goldenberg, W. J.G. Oyen, F. H.M. Corstens, and O. C. Boerman Pretargeting with Bispecific Anti-Renal Cell Carcinoma x Anti-DTPA(In) Antibody in 3 RCC Models J. Nucl. Med., March 1, 2005; 46(3): 495 - 501. [Abstract] [Full Text] [PDF]

				F. G. van Schaijk, E. Oosterwijk, A. C. Soede, W. J. G. Oyen, W. J. McBride, G. L. Griffiths, D. M. Goldenberg, F. H. M. Corstens, and O. C. Boerman Pretargeting with Labeled Bivalent Peptides Allowing the Use of Four Radionuclides: 111In, 131I, 99mTc, and 188Re Clin. Cancer Res., September 1, 2003; 9(10): 3880S - 3885. [Abstract] [Full Text] [PDF]

				K. S. Kolbert, T. Watson, C. Matei, S. Xu, J. A. Koutcher, and G. Sgouros Murine S Factors for Liver, Spleen, and Kidney J. Nucl. Med., May 1, 2003; 44(5): 784 - 791. [Abstract] [Full Text] [PDF]

				O. C. Boerman, F. G. van Schaijk, W. J.G. Oyen, and F. H.M. Corstens Pretargeted Radioimmunotherapy of Cancer: Progress Step by Step J. Nucl. Med., March 1, 2003; 44(3): 400 - 411. [Abstract] [Full Text] [PDF]

				R. M. Sharkey, W. J. McBride, H. Karacay, K. Chang, G. L. Griffiths, H. J. Hansen, and D. M. Goldenberg A Universal Pretargeting System for Cancer Detection and Therapy Using Bispecific Antibody Cancer Res., January 15, 2003; 63(2): 354 - 363. [Abstract] [Full Text] [PDF]

				C.-H. Chang, R. M. Sharkey, E. A. Rossi, H. Karacay, W. McBride, H. J. Hansen, J.-F. Chatal, J. Barbet, and D. M. Goldenberg Molecular Advances in Pretargeting Radioimunotherapy with Bispecific Antibodies Mol. Cancer Ther., May 1, 2002; 1(7): 553 - 563. [Abstract] [Full Text] [PDF]

				G. Liu, K. Mang'era, N. Liu, S. Gupta, M. Rusckowski, and D. J. Hnatowich Tumor Pretargeting in Mice Using 99mTc-Labeled Morpholino, a DNA Analog J. Nucl. Med., March 1, 2002; 43(3): 384 - 391. [Abstract] [Full Text] [PDF]